References
- Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061–5
- Hughes WT, Pizzo PA, Wade JC et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl 1):206–15
- Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988;1:139–56
- Klastersky J, Zinner SH. Synergistic combinations of antibiotics in Gram-negative bacillary infections. Rev Infect Dis 1982;4:294–8
- Brown AE, Kiehn TE, Armstrong D. Bacterial resistance in the patient with neoplastic disease. Infect Dis Clin Pract 1995;4: 136–44
- Sepkowitz KA, Brown AE, Armstrong D. Empirical therapy for febrile, neutropenic patients: persistence of susceptibility of Gram-negative bacilli to aminoglycoside antibiotics. Clin Infect Dis 1994;19:810–11
- De Jongh CA, Joshi JH, Newman KA. Antibiotic synergism and response in Gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986;80(Suppl 5C):96–100
- EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692–8
- Cometta A, Zinner S, De Bock R et al. Piperacillin–tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445–52
- Furno P, Bucaneve G, Del Favero A. Monotherapy or amino-glycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231–42
- Norrby SR. Carbapenems. Med Clin North Am 1995;79: 745–59
- Moellering RC Jr, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 1989;24(Suppl A):1–7
- Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Investig Drugs 2002;11:529–44
- Bodey GP, Elting L, Jones P et al. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987;60:255–62
- Rolston KVI, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283–91
- Liang R, Yung R, Chiu E et al. Ceftazidime versus imipenemcilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1336–41
- Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843–54
- Winston DJ, Winston H, Bruckner DA et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849–59
- Raad I, Whimbey E, Rolston K et al. A comparison of imipenem to aztreonam with vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996;77:1386–94
- Bodey GP, Abi-Said D, Rolston KV et al. Imipenem versus cefoperazone-sulbactam both combined with vancomycin as therapy for fever in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625–34
- Bodey GP, Alvarez ME, Jones GP et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986;30:211–4
- Liang R, Yung R, Chau PY et al. Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother 1988;22:765–70
- Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents 2003;21:393–402
- Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996;37:975–86
- National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Villanova, PA, USA: NCCLS, 1994
- Pizzo PA, Armstrong D, Bodey G et al. From the Immuno-compromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990;161:397–401
- Canadian Coordinating Office for Health Technology Assessment. A guidance document for the costing process. Version 1.0. Ottawa, Ontario, Canada: CCOHTA, 1996
- World Health Organization. Handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO, 1979
- Sanz MA, Lopez J, Lahuerta JJ et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002;50:79–88
- Del Favero A, Menichetti F, Martino P et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillintazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295–1301
- Micozzi A, Nucci M, Venditti M et al. Piperacillin/tazobactam/ amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1–8
- Dietrich ES, Patz E, Frank U, Daschner FD. Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes of neutropenic cancer patients in Germany. Infection 1999; 27:23–7
- Elting LS, Rubenstein EB, Rolston K et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications to quality and cost of care. J Clin Oncol 2000;18:3699–706